A Phase II, Open-Label, Randomized Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic ER+ /HER2 - Breast Cancer Resistant to Aromatase Inhibitor Therapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Mar 2017
At a glance
- Drugs GDC 0810 (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Genentech
- 07 Jun 2017 Biomarkers information updated
- 07 Mar 2017 Planned End Date changed from 1 Mar 2018 to 2 Jan 2018.
- 07 Mar 2017 Planned primary completion date changed from 1 Mar 2018 to 2 Jan 2018.